INSM Stock Overview
A biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.67 |
| 52 Week High | US$80.53 |
| 52 Week Low | US$21.92 |
| Beta | 1.12 |
| 11 Month Change | 0.54% |
| 3 Month Change | -8.02% |
| 1 Year Change | 206.24% |
| 33 Year Change | 137.41% |
| 5 Year Change | 217.06% |
| Change since IPO | -55.96% |
Recent News & Updates
Recent updates
Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
Nov 20Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up
Sep 12
Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
Aug 28Is Insmed (NASDAQ:INSM) A Risky Investment?
Aug 10Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up
May 29Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
May 28Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 25Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected
Dec 18Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely
Jul 28Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)
Jul 01Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?
Apr 18A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)
Feb 23Insmed inks financing agreements to raise $500M
Oct 19Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?
Oct 17An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued
Sep 20Insmed rises 16% on better-than-expected Q2 result
Aug 04Shareholder Returns
| INSM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | -6.5% | -1.0% |
| 1Y | 206.2% | 14.6% | 30.3% |
Return vs Industry: INSM exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: INSM exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| INSM volatility | |
|---|---|
| INSM Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INSM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INSM's weekly volatility has decreased from 18% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 912 | Will Lewis | www.insmed.com |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
Insmed Incorporated Fundamentals Summary
| INSM fundamental statistics | |
|---|---|
| Market cap | US$13.19b |
| Earnings (TTM) | -US$864.28m |
| Revenue (TTM) | US$342.96m |
37.9x
P/S Ratio-15.0x
P/E RatioIs INSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INSM income statement (TTM) | |
|---|---|
| Revenue | US$342.96m |
| Cost of Revenue | US$78.03m |
| Gross Profit | US$264.92m |
| Other Expenses | US$1.13b |
| Earnings | -US$864.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.83 |
| Gross Margin | 77.25% |
| Net Profit Margin | -252.01% |
| Debt/Equity Ratio | 230.6% |
How did INSM perform over the long term?
See historical performance and comparison